MRx-4DP0004

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
MRx-4DP0004
Accession Number
DB15751
Description

MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.

Type
Biotech
Groups
Investigational
Synonyms
  • Bifidobacterium breve
External IDs
  • MRx-4DP0004

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

MRx-4DP0004 is an immunomodulatory therapy with anti-viral activity that simultaneously downregulates molecules associated with hyper-inflammatory responses. It reduces neutrophilic and eosinophilic infiltration in the lungs, in addition to a reduction in peribronchiolar and perivascular immunopathology without the side effects associated with immunosuppressants. A study of MRx-4DP0004 also demonstrated specifics of the biotherapeutic increasing lung D4+CD44+ cells and CD4+FoxP3+ cells, decreasing activated CD11b+ dendritic cells, and reducing pro-inflammatory cytokines and chemokines involved in neutrophil migration. MRx-4DP0004 is currently being investigated for severe asthma management, however, the specific mechanism of action is currently unknown.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
L07O8T40TE
CAS number
Not Available

References

General References
  1. Raftis EJ, Delday MI, Cowie P, McCluskey SM, Singh MD, Ettorre A, Mulder IE: Bifidobacterium breve MRx0004 protects against airway inflammation in a severe asthma model by suppressing both neutrophil and eosinophil lung infiltration. Sci Rep. 2018 Aug 13;8(1):12024. doi: 10.1038/s41598-018-30448-z. [PubMed:30104645]
  2. Contract Pharma: 4D Pharma Begins Phase II COVID-19 Study [Link]
  3. 4D Pharma: Poster presentation on MRx-4DP0004 [Link]
RxNav
2110011

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentBifidobacterium Breve / Gut Microbiome / Infantile Colics / Probiotic1
4CompletedTreatmentObesity, Childhood1
2RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
2, 3CompletedPreventionDiarrhea1
1, 2CompletedPreventionGluten Enteropathy1
1, 2RecruitingTreatmentAsthma1
Not AvailableUnknown StatusBasic ScienceIrritable Bowel Syndrome (IBS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionOral6.6 mg/10ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 16:01 / Updated on August 13, 2020 01:02

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates